[Post-COVID-19 asthenic syndrome]. / Astenicheskii sindrom u patsientov, perenesshikh COVID-19.
Zh Nevrol Psikhiatr Im S S Korsakova
; 121(4): 25-30, 2021.
Article
in Russian
| MEDLINE | ID: covidwho-1244382
ABSTRACT
OBJECTIVE:
To study the features of asthenic syndrome and the possibilities of its therapy in patients in the post-covid period. MATERIAL ANDMETHODS:
The study included 129 patients with an average age of 49.8±8.9 years who had undergone COVID-19 using a continuous sample method. Patients for the study were selected at the clinical bases of outpatient clinics in Samara (Russia) in July-August 2020. All patients signed an informed consent form prior to enrollment. Patients were randomized into two groups in the main group (n=64), ethylmethylhydroxypyridine succinate (Neurox) was prescribed 1 tablet (125 mg) 3 times a day for 4 weeks; in the comparison group (n=65), medical drugs (MD) did not contain substances from the pharmacological group related to antihypoxants/antioxidants/nootropics. Three visits (V) were conducted the first (V1) - the period of inclusion, the second (V2) - after 14 days, the third (V3) - on the 28th day from the start of therapy. The dynamics of the general state (weakness, fatigue, concentration, dizziness, headache, sleep disorders) were evaluated on a visual-analog scale (VAS), the assessment of the subjective feeling of severity of asthenia (fatigue, physical and mental fatigue, decreased motivation and activity) - on Multidimensional Fatigue Inventory (MFI-20), cognitive functions - on Mini-Mental State Examination (MMSE), vegetative tone - according to the Kerdo index.RESULTS:
At the end of the study (V3), statistically significant changes in indicators (VAS, MFI-20) were obtained only in the main group patients; no statistically significant differences were obtained for the Kerdo index. Analysis of the MMSE data revealed a decrease in cognitive functions in both groups, which may be associated with pseudocognitive deficits due to asthenia.CONCLUSIONS:
We have obtained evidence of a high incidence of asthenic syndrome after COVID-19. Against the background of taking Neurox, there was a decrease in the severity and expression of asthenia symptoms.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Asthenia
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Adult
/
Humans
/
Middle aged
Country/Region as subject:
Asia
/
Europa
Language:
Russian
Journal:
Zh Nevrol Psikhiatr Im S S Korsakova
Journal subject:
Neurology
/
Psychiatry
Year:
2021
Document Type:
Article
Affiliation country:
Jnevro202112104125
Similar
MEDLINE
...
LILACS
LIS